65,437 trials
Heart Failure
Primary: Change in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to One Year — 0.5905 pg/mL — p=<.0001
18-42 Year Old Healthy Vaccinia-naïve Subjects
Primary: Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at the Peak Visits — 153.5; 79.3 Titer
Growth and Development
Primary: Total Number of Ill Days Due to Gastrointestinal (GI) and Respiratory Illness at Month 9 — 2.3; 8.2 Number of days — p=0.0628
COPD · Emphysema · Chronic Bronchitis
Primary: Effective Concentration (EC 50) of GRO Alpha — 1.5; 0.9; 0.6 ng/ml — p=0.05
Diarrhea
Primary: Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population — 90; 93…
Mycosis Fungoides
Primary: Treatment Responders Using Body Surface Area (BSA) at 12 Months — 44 Participants
Cystic Fibrosis
Primary: Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA — 6630; 4310; 6300; 5340 nanogram per milliliter (ng/mL)
Active Systemic Lupus Erythematosus
Primary: Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)…
Cognitive Impairment
Primary: Change Scores of Standard (Untrained) Neurocognitive Measures (Verbal Memory, Learning and Sustained Attention) — 2.29; 2.29; 0.71; 0.14 score on a scale
Shingles
Primary: Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood — 0.02 percentage of CD4 T cells
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
Sporadic Amyotrophic Lateral Sclerosis
Primary: Change in Resting Motor Threshold — -2.430; 0.805; 4.746; 1.465 percentage of maximum stimulus output — p=0.039
Sexual Dysfunction · Erectile Dysfunction
Primary: Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment — 34.52; 30.85; 34.33; 31.73 cm/sec
Psoriasis
Primary: Percentage of Participants With a Physician Global Assessment (PGA) Score ≤1 at Month 6 — 31.4; 56.3 percentage of participants — p=<0.001
Contraception
Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants